Melinda J Gooderham

97PUBLICATIONS
213CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyInnate immunityMolecular medicineToxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (97)

|Aug 28, 2026
Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials.

|Aug 07, 2026
Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REAL.

|Jun 02, 2026
Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease.

|May 23, 2026
Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings.

|May 17, 2026
Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial.

|May 16, 2026
Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial.

Pageof 17

Frequent Collaborators

17 joint publications

Kim Parnell

13 joint publications

Ronald Vender

9 joint publications

Jonathan I Silverberg

9 joint publications

H Chih-Ho Hong